Updated 2025-2026 vaccination was linked to added protection in a CDC-funded analysis that became part of a broader debate over routine vaccine monitoring.
Clinical Report: Updated COVID Shot Linked to Added Protection
Overview
Interim data from the CDC-funded VISION Network indicates that the 2025-2026 COVID-19 vaccine provides short-term protection against medically attended COVID-19 in immunocompetent adults. Vaccine effectiveness was estimated at 50% for emergency department and urgent care encounters and 55% for hospitalizations.
Background
The ongoing evolution of COVID-19 necessitates continuous evaluation of vaccine effectiveness, particularly as new variants emerge. The 2025-2026 vaccine formulation specifically targets JN.1 and JN.1-derived sublineages.
Data Highlights
Outcome
Vaccine Effectiveness
ED/UC Encounters
50%
Hospitalizations
55%
ED/UC Encounters (Age 65+)
48%
Hospitalizations (Age 65+)
53%
Key Findings
The 2025-2026 COVID-19 vaccine was associated with 50% effectiveness against COVID-19-related ED/UC encounters.
Vaccine effectiveness against COVID-19-related hospitalizations was estimated at 55%.
Among adults aged 65 years or older, vaccine effectiveness was 48% for ED/UC encounters and 53% for hospitalizations.
The study primarily reflects short-term protection, with median time since vaccination being 47 days for ED/UC encounters.
Findings suggest that increased population-level immunity may affect vaccine effectiveness estimates.
Clinical Implications
Healthcare providers should consider the short-term effectiveness of the 2025-2026 COVID-19 vaccine when advising patients.
Conclusion
The interim analysis provides data on the effectiveness of the 2025-2026 COVID-19 vaccines in immunocompetent adults.
